Center-Authored Papers

Filters: Author is Fuchs, Jonathan D  [Clear All Filters]
A
Adamson BJS, Fuchs JD, Sopher CJ, Flood DM, Johnson PR, Haynes BF, Kublin JG.  2015.  A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines.. Clinical and translational science. 8(2):166-8. Abstract
F
Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD et al..  2015.  First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).. Open forum infectious diseases. 2(3):ofv082. Abstract
Fuchs JD, Bart P-A, Frahm N, Morgan C, Gilbert PB, Kochar N, De Rosa SC, Tomaras GD, Wagner TM, Baden LR et al..  2015.  Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.. Journal of AIDS & clinical research. 6(5) Abstract
Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, Andrasik M, Sherwat A, Broder G, Mayer K, Koblin B et al..  2013.  Intentions to use pre-exposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.. Journal of acquired immune deficiency syndromes (1999). Abstract
G
Gorse GJ, Newman MJ, DeCamp A, Hay CM, De Rosa SC, Noonan E, Livingston BD, Fuchs JD, Kalams SA, Cassis-Ghavami FL.  2012.  DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.. Clinical and vaccine immunology : CVI. 19(5):649-58. Abstract
J
Jacob ST, Baeten JM, Hughes JP, Peinado J, Wang J, Sanchez J, Reid SE, Delany-Moretlwe S, Cowan F, Fuchs JD et al..  2011.  A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial.. AIDS and behavior. 15(5):897-904. Abstract
P
Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PIW, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M et al..  2010.  The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.. Science (New York, N.Y.). 330(6010):1551-7. Abstract
S
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract